Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979460 | 1.00 | LMNA (0.46) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL6885588 | 0.76 | MAPK1 (0.51) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL5468206 | 0.76 | APAF1 (0.62) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL13068123 | 0.75 | FEN1 (0.40) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL12193480 | 0.75 | MTOR (0.50) | CYP3A4ALDH1A1MAPTADORA2AADORA2B | |
| SCHEMBL18850911 | 0.73 | LMNA (0.49) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL17813483 | 0.73 | LMNA (0.45) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL30328814 | 0.73 | LMNA (0.49) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL1503016 | 0.72 | DAO (0.71) | LMNACYP3A4PMP22MEN1PABPC1 | |
| SCHEMBL22836260 | 0.72 | LMNA (0.44) | LMNACYP3A4PMP22ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120476110-B | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | SHANGHAI HANSOH BIOMEDICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| CN-120019043-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025007915-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119264042-A | Cyclopentane derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2022173033-A1 | 4-AMINOQUINAZOLINE COMPOUNDS | アステラス製薬株式会社 | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, NOS1 | LMNA 1095/4885CYP3A4 104/4885PMP22 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.